Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises FCG in connection with the acquisition of Algorithmica Research
Mandate

Vinge advises FCG in connection with the acquisition of Algorithmica Research

June 22, 2020 M&A Commercial Agreements Employment and Benefits Banking and Finance

Vinge has advised Bridgepoint and FCG in connection with the acquisition of Algorithmica Research AB, a software technology provider of risk management and quantitative financial analytical solutions for the financial services industry.

Through the acquisition, FCG, leading Northern European experts in Governance, Risk & Compliance (“GRC”) with a strong track record of providing new and customer centered services to clients in the finance and insurance sector, adds new capabilities to enhance and further expand its technology area and product offerings.

Vinge’s team consisted primarily of partner Daniel Rosvall and associates Michaela Cronemyr, Fredric Reissmüller, Carl Fredrik Wachtmeister (M&A), Lisa Hörnqvist (Commercial Agreements), Lisa Ullman (Employment), Nathalie Hughes (VDR-assistant) also partner Alber Wållgren along with associates Josefin Lanker and Hannes Pettersson (Banking & Financing).

 

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024